CERE Overview
Upcoming Projects (CERE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CERE)
-
A Second Opinion: Discussing Cerevel Therapeutics Topline Results for Tavapadon in the Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Tickers: CERE, ABBV
Executed On: May 09, 2024 at 12:00 PM EDT -
Discussing Cerevel Therapeutics Topline Results for Tavapadon in the Phase 3 Adjunctive Trial for People Living with Parkinson’s Disease
Tickers: CERE, ABBV
Executed On: May 01, 2024 at 11:00 AM EDT -
Looking at the standard of care for Parkinson's Disease patients and the potential of Cerevel Therapeutics orally-administered, selective partial agonist of the dopamine D1 and D5 receptor, Tavapadon
Ticker: CERE
Executed On: Nov 09, 2022 at 01:00 PM EST
Upcoming & Overdue Catalysts (CERE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (CERE)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
